Extensively drug-resistant tuberculosis: Are we learning from history or repeating it?

Clinical Infectious Diseases

Volumn 45, Issue 3, 2007, Pages 338-342

  Hamilton, Carol Dukes ^a,b,j   Sterling, Timothy R ^c   Blumberg, Henry M ^d   Leonard, Michael ^d   McAuley, James ^e   Schlossberg, David ^f,g   Stout, Jason ^a,b   Huitt, Gwen ^h,i  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b North Carolina Tuberculosis Control Program   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f Philadelphia TB Control Program   (United States)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL TRANSMISSION; BUDGET; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FUNDING; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; LABORATORY DIAGNOSIS; MORTALITY; POPULATION RISK; PREVENTION AND CONTROL; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RESEARCH; REVIEW; RISK FACTOR; SOUTH AFRICA; TREATMENT PLANNING; TUBERCULOSIS; TUBERCULOSIS CONTROL;

DEVELOPING COUNTRIES; DRUG RESISTANCE, BACTERIAL; HUMANS; PUBLIC HEALTH; TUBERCULOSIS; UNITED STATES;

EID: 34547118552     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519292     Document Type: Review

References (28)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367:938-40.
2. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
3. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13:380-7.
4. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55:1176.
5. Menzies D. Controlling tuberculosis among foreign born within industrialized countries: expensive band-aids. Am J Respir Crit Care Med 2001; 164:914-5.
6. Falzon D, Ait-Belghiti F. What is tuberculosis surveillance in the European Union telling us? Clin Infect Dis 2007; 44:1261-7.
7. Centers for Disease Control and Prevention. Trends in tuberculosis - United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55: 305-8.
8. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
9. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276:1229-35.
10. Driver CR, Frieden TR, Bloch AB, Onorato IM. Drug resistance among tuberculosis patients, New York City, 1991 and 1992. Public Health Rep 1994; 109:632-6.
11. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006; 6: 710-25.
12. Kochi A. Tuberculosis control - is DOTS the health breakthrough of the 1990s? World Health Forum 1997; 18:225-34.
13. Apers L, Mutsvangwa J, Magwenzi J, et al. A comparison of direct microscopy, the concentration method and the Mycobacteria Growth Indicator Tube for the examination of sputum for acid-fast bacilli. Int J Tuberc Lung Dis 2003; 7:376-81.
14. Peterson EM, Nakasone A, Platon-DeLeon JM, Jang Y, de la Maza LM, Desmond E. Comparison of direct and concentrated acid-fast smears to identify specimens culture positive for Mycobacterium spp. J Clin Microbiol 1999; 37:3564-8.
15. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 5:225-32.
16. Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14: 1219-28.
17. Enarson DA, Grzybowski S, Dorken E. Failure of diagnosis as a factor in tuberculosis mortality. Can Med Assoc J 1978; 118:1520-2.
18. Comstock GW, Woolpert SF. Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population. Arch Environ Health 1972; 25:333-7.
19. Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by chest clinic service. Am Rev Respir Dis 1971; 104:605-8.
20. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2006; 2:CD003343.
21. Farmer P. DOTS and DOTS-plus: not the only answer. Ann N Y Acad Sci 2001; 953:165-84.
22. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-45.
23. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539-50.
24. Rosenthal IM, Nuermberger EL, Williams K, Vernon A, Bishai W, Grosset JH. Twice-weekly rifapentine (P)-containing regimens produce stable cure after 4 months in murine TB. Proc Am Thorac Soc 2006; 3:A744.
25. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-7.
26. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-8.
27. Treatment Action Group. TB/HIV project. Available at: http://www.aidsinfonyc.org/tag/ tbhiv/.
28. Glickman SW, Rasiel EB, Hamilton CD, Kubataev A, Schulman KA. Medicine: a portfolio model of drug development for tuberculosis. Science 2006; 311:1246-7.